-
Mashup Score: 0Current treatment landscape for kidney cancer - 3 year(s) ago
Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, gives an outline of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Toni Choueiri on RCC Treatment With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib - The ASCO Post - 3 year(s) ago
2021 Genitourinary Cancers Symposium Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results of the CLEAR study, which showed that for first-line treatment of advanced renal cell carcinoma, lenvatinib plus pembrolizumab improved outcomes vs sunitinib. Lenvatinib plus everolimus also improved progression-free…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Toni K. Choueiri, MD, on RCC: Treatment With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib https://t.co/nBDbphwu1r #GU21 #kcsm #oncology #cancer @DrChoueiri @DanaFarberNews https://t.co/bMRck8B8GH
-
-
Mashup Score: 2CLEAR Trial: Is Lenvatinib Plus Pembrolizumab the Best First-Line Immunotherapy Doublet in Metastatic Renal Cell Carcinoma? - The ASCO Post - 3 year(s) ago
Nizar M. Tannir, MD, FACP Andrew W. Hahn, MD Pavlos Msaouel, MD, PhD At the 2021 Genitourinary Cancers Symposium, Motzer et al presented the clinical results of the CLEAR trial, adding a novel regimen, lenvatinib plus pembrolizu-mab, to the growing armamentarium of first-line treatments for patients with metastatic…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Nizar Tannir, Dr. Andrew Hahn and Dr. Pavlos Msaouel discuss the results of the CLEAR clinical trial and what they mean for the treatment of metastatic renal cell carcinoma: https://t.co/S8gt8oyQ3a @ASCOPost @OncHahn @PavlosMsaouel #GU21 #EndCancer
-
-
Mashup Score: 0Latest genomic insights for prostate cancer treatment - 3 year(s) ago
Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses the role of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: Latest genomic insights for prostate cancer treatment w/ Robert Jones of @UofGlasgow 👉 https://t.co/zVFCl6mE6g👈 @VJOncology @OncoAlert @ASCO #GU21 #UroSoMe #UroOnc #ProstateCancer #PCsm #OncoAlert #NCRM21 #ResearchSavesLives
-
-
Mashup Score: 4Neoadjuvant atezolizumab for non-metastatic urothelial cancer - 3 year(s) ago
Vadim Koshkin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an update on the Phase II…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: Neoadjuvant atezolizumab for non-metastatic urothelial cancer w/ @koshkin85 of @UCSFCancer 👉 https://t.co/uMULDQvOkx👈 @VJOncology @OncoAlert @ASCO #GU21 #GUsm #BLCsm #UroOnc #UroSoMe #TrialUpdate #OncoAlert #Oncology #ClinOnc #MedOnc #NCRM21 #ResearchSavesLives
-
-
Mashup Score: 2
Tian Zhang, MD, Duke Cancer Center, Durham, NC, discusses the PAPMET study (NCT02761057), which is investigating MET inhibitors in patients…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: PAPMET: MET inhibitors in treating papillary renal cell carcinoma w/ @TiansterZhang of @DukeCancer 👉 https://t.co/xOcJKRWuLD👈 @VJOncology @OncoAlert @ASCO #GU21 #UroSoMe #UroOnc #KidneyCancer #KCsm #OncoAlert #Oncology #TrialUpdate #NCRM21 #ResearchSavesLives
-
-
Mashup Score: 0Checkpoint inhibitors for metastatic urothelial cancer - 3 year(s) ago
Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses therapy with immune checkpoint inhibitors (ICIs) for…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: Checkpoint inhibitors for metastatic urothelial cancer w/ Arlene Siefker-Radtke of @MDAndersonNews 👉 https://t.co/7rm9e4ya2r👈 @VJOncology @OncoAlert @ASCO #GU21 #GUsm #BLCsm #UroOnc #UroSoMe #TrialUpdate #OncoAlert #Oncology #ClinOnc #NCRM21 #ResearchSavesLives
-
-
Mashup Score: 0
Jana McHugh, MD, of The Institute of Cancer Research, London, UK, gives an update on the BARCODE1 pilot study (NCT03158922)…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: BARCODE1: polygenic risk score for targeted screening for prostate cancer w/ Jana McHugh of @ICR_London 👉 https://t.co/xkz7r1XEkS👈 @VJOncology @OncoAlert @ASCO #GU21 #UroSoMe #UroOnc #ProstateCancer #PCsm #OncoAlert #Oncology #TrialUpdate #NCRM21 #ResearchSavesLives
-
-
Mashup Score: 0Toward more personalized treatment in prostate cancer: The CCR score predicts metastasis and guides treatment decisions after radiation - 3 year(s) ago
Toward more personalized treatment in prostate cancer: The CCR score predicts metastasis and guides treatment decisions after radiation
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The CCR score has proven accurate in studies and can guide post-radiation treatment decisions in practice. A review on this week’s Blood & Cancer podcast. https://t.co/pi0CMi2Efo @davidhenrymd @prostatemd @huntsmancancer @Huntsman_GU @ASCO #GU21 #pcsm https://t.co/71KzfKsXED
-
-
Mashup Score: 5
Tian Zhang, MD, Duke Cancer Center, Durham, NC, discusses new studies showing the potential for vascular endothelial growth factor receptor…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: VEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancer w/ @TiansterZhang of @DukeCancer 👉 https://t.co/0t0v6fLFu6👈 @VJOncology @OncoAlert @ASCO #GU21 #UroSoMe #UroOnc #KidneyCancer #KCsm #OncoAlert #Oncology #NCRM21 #ResearchSavesLives
-
VIDEO: Current treatment landscape for kidney cancer w/ Robert Jones of @UofGlasgow 👉 https://t.co/UfP6j1zyxo👈 @VJOncology @OncoAlert @ASCO #GU21 #UroSoMe #UroOnc #KidneyCancer #KCsm #OncoAlert #NCRM21 #ResearchSavesLives